Acute myelogenous leukemia (AML) remains one of the most formidable challenges in modern oncology, characterized by a rapid progression and…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Discovery of Fam102a as a Dual Regulator of Bone Remodeling Offers New Horizons for Osteoporosis Treatment
In a landmark study that promises to redefine the landscape of musculoskeletal medicine, researchers at the Institute of Science Tokyo…
Read More
Idvynso Secures FDA Approval, Charting a New Course in HIV Treatment While Biktarvy Maintains Market Dominance
MSD (Merck & Co) has achieved a significant milestone in the fight against Human Immunodeficiency Virus (HIV) with the U.S.…
Read More
Honeycomb-Inspired 3D-Printed Soft Electrodes Pave Way for Personalized Brain Monitoring and Neurological Treatment
The realm of neural interfaces, critical for understanding and treating a myriad of neurological conditions, has long grappled with a…
Read More
The Evolving Landscape of Locally Advanced Head and Neck Squamous Cell Carcinoma Treatment Presents New Avenues for Innovation
The treatment paradigm for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is undergoing a significant transformation, driven…
Read More
Molecular Switch Discovery in Sperm Metabolism Offers New Pathways for Infertility Treatment and Non-Hormonal Contraception
Researchers at Michigan State University (MSU) have identified a critical molecular "switch" that triggers a massive surge in sperm energy…
Read More
Breakthrough Combination Therapy Offers New Hope for Acute Myelogenous Leukemia Treatment Through Epigenetic Reprogramming
Acute Myelogenous Leukemia (AML) has long remained one of the most formidable challenges in oncology, characterized by its rapid progression…
Read More
Aligos Therapeutics Licenses Pevifoscorvir Sodium to Xiamen Amoytop Biotech for Greater China, Bolstering HBV Treatment Landscape
Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop Biotech, granting the Chinese biopharmaceutical company the rights…
Read More
Hydrogen Sulfide and CSE Protein Research Offers New Therapeutic Target for Alzheimer’s Disease Treatment and Brain Health
Researchers at Johns Hopkins Medicine have announced that a newly funded study by the National Institutes of Health (NIH) is…
Read More
